Stock Analiz

Axsome Therapeutics, Inc. (AXSM) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

Net income in fiscal 2025 was -$183M, a net margin of -28.7%; the best year in this period was 2016 with -$27M.

Over the twelve months to September 30, 2026, revenue was $865M and net income -$157M.

Free cash flow was -$94M in fiscal 2025 and positive in 0 of the 10 years shown.

The diluted share count rose 160% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2022: $50M20222023: $271M20232024: $386M20242025: $638M2025$638M
Net income
2016: -$27M162017: -$29M172018: -$31M182019: -$68M192020: -$103M202021: -$130M212022: -$187M222023: -$239M232024: -$287M242025: -$183M25-$183M
Free cash flow
2016: -$21M162017: -$26M172018: -$30M182019: -$46M192020: -$79M202021: -$109M212022: -$117M222023: -$146M232024: -$129M242025: -$94M25-$94M
EPS (diluted)
2016: $-1.42162017: $-1.27172018: $-1.15182019: $-2.01192020: $-2.77202021: $-3.47212022: $-4.60222023: $-5.27232024: $-5.99242025: $-3.6825$-3.68

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$865M$638M$386M$271M$50M——————
Gross profit————$45M——————
Operating income-$151M-$167M-$281M-$232M-$180M-$125M-$99M-$67M-$33M-$27M-$28M
Net income-$157M-$183M-$287M-$239M-$187M-$130M-$103M-$68M-$31M-$29M-$27M
EPS (diluted)$-3.05$-3.68$-5.99$-5.27$-4.60$-3.47$-2.77$-2.01$-1.15$-1.27$-1.42
R&D$198M$183M$187M$98M$58M$58M$70M$54M$23M$20M$21M
Revenue growth—+65.5%+42.5%+440.8%———————

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$82M-$93M-$128M-$145M-$117M-$108M-$78M-$46M-$30M-$26M-$21M
Capital spending-$839000-$480000-$270000-$582000-$702000-$308000-$45891-$16121-$32696-$9898-$104561
Free cash flow-$83M-$94M-$129M-$146M-$117M-$109M-$79M-$46M-$30M-$26M-$21M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$100M$94M$85M$63M$38M$21M$15M$6M$2M$2M$2M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$323M$315M$386M$201M$86M$184M$220M———
Debt—$211M$189M$188M$95M$51M$52M$20M$7M$10M$10M
Equity—$88M$57M$191M$110M$16M$114M$179M$937921$17M$22M
Total assets—$690M$568M$588M$331M$88M$186M$221M$15M$36M$38M
Shares (diluted)52M50M48M45M41M38M37M34M27M23M19M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin————89.6%——————
Operating margin-17.5%-26.1%-72.7%-85.7%-359.3%——————
Net margin-18.2%-28.7%-74.5%-88.4%-374.0%——————
FCF margin-9.5%-14.7%-33.4%-53.8%-234.2%——————
ROIC—-55.5%-90.2%-48.3%-87.7%-188.2%-47.3%-26.7%-330.6%-80.5%-69.5%
ROE—-207.5%-503.8%-125.3%-170.8%-834.3%-90.4%-38.2%-3301.5%-173.1%-126.1%

Frequently asked questions

What is Axsome Therapeutics’s annual revenue?

$638M in fiscal 2025 and $865M over the twelve months to September 30, 2026.

How much profit does Axsome Therapeutics make?

Net income was -$183M in fiscal 2025 (net margin -28.7%).

Is Axsome Therapeutics’s revenue growing?

Yes: revenue rose 65.5% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.